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The objective of this study is to determine the progress and trends in the treatment and survival of women with early-stage (I–II)
epithelial ovarian cancer. Data were obtained from the SEER database between 1988 and 2001. Kaplan–Meier and Cox regressions
methods were employed for statistical analyses. Of the 8372 patients, the median age was 57 years (range: 12–99 years). A total of
6152 patients (73.4%) presented with stage I and 2220 (26.5%) with stage II disease. Over the periods 1988–1992, 1993–1997, and
1998–2001, 3-year disease-specific survivals increased from 86.1 to 87.2 to 88.8% (P¼0.076). The number of patients that
underwent lymphadenectomy has increased significantly from 26.2 to 38.7 to 54.2% over the study period (Po0.001). Of those
patients who underwent staging procedures with lymphadenectomy, there was no improvement in survival over the three study
periods (from 93.2 to 93.5 to 93.1%; P¼0.978). On multivariate analysis, younger age, nonclear cell histology, earlier stage, lower
grade, surgery, and lymphadenectomy were significant independent prognostic factors for improved survival. After adjusting for
surgical staging with lymphadenectomy, the year of diagnosis was no longer an important prognostic factor. In conclusion, the use of
lymphadenectomy during surgery for early-stage ovarian cancer has doubled over the last 14 years. The marginal improvement in
survival demonstrated over time is potentially attributed to the increased use of staging procedures with lymphadenectomy.
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Ovarian cancer is the fifth leading cause of cancer death in women
and the second most common gynaecologic cancer in the United
States (Jemal et al, 2006). In 2007, an estimated 22430 new
epithelial ovarian cancers were diagnosed in the United States and
approximately one-third had FIGO (International Federation of
Obstetrics and Gynecology) stage I and II disease with a survival
rate ranging from 70 to 90% (Heintz et al, 2006; Jemal et al, 2006).
Although the survival of early-stage disease is significantly higher
than those with advanced cancers, approximately 20–30% of
patients with early-stage cancers will succumb to their disease
(Nguyen et al, 1993; Hoskins et al, 1994; Kosary, 1994; Averette
et al, 1995; McGuire et al, 1996; Heintz et al, 2006).
Prior reports have shown that age, stage, cell type, tumour
grade, large volume ascites, and dense adhesions are important
clinical and pathological prognostic factors (Dembo et al, 1990;
Sevelda et al, 1990; Young et al, 1990; Finn et al, 1992; Bertelsen
et al, 1993; Vergote et al, 1993; Sjovall et al, 1994; Ahmed et al,
1996; Holschneider and Berek, 2000; Trope et al, 2000). Recently,
Chan et al (2008) reported on patients with high-risk early-stage
patients defined as stage I, grade 3; stage IC; stage II; or clear cell
epithelial ovarian cancer after adjuvant therapy from two
Gynecologic Oncology Group studies. These authors also found
that age, stage, grade, and cytology are important prognostic
factors in these patients (Chan et al, 2008).
Despite the fact that advanced stage disease is associated with a
poorer survival, a recent study showed that these women had a
significant improvement in 5-year survival from 25.4 to 29.4% over
time. However, this study was not able to demonstrate a
statistically significantly benefit in survival in women with early-
stage cancers (Chan et al, 2006). The objective of this study was to
evaluate the demographic, clinicopathologic, treatment, and
survival trends of patients with early-stage epithelial ovarian
cancer, and to determine the prognostic factors responsible for
specific survival trends.
MATERIALS AND METHODS
Demographic, clinicopathologic, treatment, and survival informa-
tion of women diagnosed with stage I–II epithelial ovarian cancer
during the period from 1988 through 2001 were identified from the
Surveillance, Epidemiology and End Results (SEER) (2005) of the
National Cancer Institute. The SEER program is an epidemiologic
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ssurveillance system sponsored by the National Cancer Institute
consisting of population-based tumour registries that routinely
collect information on all incidents of cancer occurring in persons
residing in SEER areas of the US. Patient demographic data, cancer
data (such as histology, stage, and grade), diagnosis date, surgical
treatment, and radiation therapy recommended and/or provided
within 4 months of diagnosis, follow-up of vital status, and cause
of death, if applicable is recorded. The SEER data do not contain
information about comorbidity or treatments received beyond the
4 months following diagnosis. As of 2002, the SEER areas include
the states of Connecticut, Hawaii, Iowa, New Mexico, and Utah, as
well as the metropolitan areas of Detroit, San Francisco – Oakland,
Los Angeles, San Jose, Atlanta, and Seattle – Puget Sound. The
latest expansion includes the addition of areas in four states –
Kentucky, Louisiana, New Jersey, and the remainder of California.
The SEER program encompasses 25% of the US population in
varied demographic areas.
In all, 8372 women were diagnosed with early-stage ovarian
carcinoma from 1988 to 2001 and were divided into three time
intervals: 1988–1992, 1993–1997, and 1998–2001. Factors includ-
ing age at diagnosis, race, marital status, stage, tumour histology,
grade of disease, type of surgery, and disease-specific survival were
extracted. Race was classified into four groups, including
Caucasian, African American, Asian, and Hispanic.
w
2 tests were performed to analyse trends in the study cohort
over the three time periods, 1988–1992, 1993–1997, and 1998–
2001. Kaplan–Meier analyses for 3-year survival were performed
on the 1988–1992, 1993–1997, and 1998–2001 time intervals. The
outcome of interest was death from ovarian cancer as determined
by the underlying cause of death on the death certificate. Thus,
time to death was censored in women who died from causes other
than ovarian cancer and who were alive at last follow-up. Cox
proportional hazards were used for multivariable analyses. Two-
tailed tests at P-values less than 0.05 were considered significant.
All data were analysed using SPSS 15.0 (SPSS, Chicago, IL, USA)
and SAS (version 6.12; SAS Inc., Cary, NC, USA).
RESULTS
In all, 8372 women were diagnosed with early-stage ovarian
carcinoma from 1988 to 2001. Table 1 shows demographic and
clinical characteristics of these women. Median age was 57 years
with 66.6% 50 years of age or older. Across the three time intervals,
1988–1992, 1993–1997, and 1998–2001, there was an increase in
the proportion of Hispanics and Asians diagnosed with early-stage
cancers (Po0.001). More specifically, the proportion of Cauca-
sians diagnosed with ovarian cancer decreased from 84.6 to 76.8 to
74.4%. Conversely, the proportion of Asians increased from 4.7
to 7.8 to 8.9% and the proportion of Hispanics increased from 4.8 to
7.6 to 8.5%. The number of patients that underwent lymphade-
nectomy has increased significantly from 26.2 to 38.7 to 54.2% over
the study period (Po0.001). In all, 73.4% were categorised as stage
I and 26.5% were categorised as stage II disease. There was no
significant change in the proportion of cases, which were stage I or
II over the three time periods (P¼0.253). Histologically, 26.4%
were serous, 26.6% endometrioid, 19.1% mucinous, 11.2% clear
cell, and 16.6% were other epithelial cell types. An increase in
the proportion of serous and endometrioid histology was seen
in the latter time period, whereas there was a decrease in the
mucinous subtype (Po0.001). A total of 20.3% of women had
grade 1, 25.8% grade 2, and 26.5% had grade 3 disease. There was
an increase in the percentage of grade 3 disease throughout the
years (from 22.5 to 27.4 to 29.3%; P¼0.010).
For women who were younger than 50 years of age, 3-year
survival was 93.1% compared with 84.2% for those who were 50
years old and older (Po0.001). Three-year disease-specific
survival among Hispanics, Asians, Caucasians, and African
Americans also differed (88.8 vs 89.4 vs 87.1 vs 84.5%)
(P¼0.005). Stage I patients had a significantly improved survival
at 91.8% compared with 74.2% in those with stage II disease
(Po0.001) (Figure 1). Comparing the four major epithelial
histologic cell types, endometrioid has a statistically significant
increase in 3-year disease-specific survival compared with the
other histologies as seen in Table 2 and Figure 2 (P¼0.015). Grade
1 tumours were found to have a higher 3-year disease-specific
survival at 96.4% compared with grades 2 and 3, at 92.4 and 82.0%,
respectively (Po0.001).
Over the 3 time intervals from 1988 to 1992, 1993 to 1997, and
1998 to 2001, women diagnosed with early-stage epithelial ovarian
carcinoma had a marginal improvement in survival from 86.1 to
87.2 to 88.8% (P¼0.076) (Figure 3). During these time periods, the
3-year survival was estimated based on age, race, surgery,
lymphadenectomy, stage, histologic cell type, and grade of disease
for each of the time periods (Table 2). Of note, there was a survival
benefit in the women X50 years (P¼0.048), endometrioid
histology (P¼0.015), and grade 3 disease (Po0.001) over the
three time periods. Although the use of lymphadenectomy has
increased over time, of those patients who underwent staging
procedures with lymphadenectomy, there was no improvement in
survival over the three periods (from 93.2 to 93.5 to 93.1%;
P¼0.978). A lack of significant improvement in disease-specific
survival over the three time periods studied was also seen when
separate analyses were performed for stage I and II patients with or
without lymphadenectomy (Table 2).
In our multivariate model, year of diagnosis, younger age,
surgery, earlier stage, nonclear cell histology, and lower grade were
significant independent prognostic factors for improved survival
(Table 3A). However, after adjusting for surgical staging with
lymphadenectomy, the year of diagnosis had a marginal sig-
nificance (HR¼0.99, CI: 0.97–1.00; P¼0.098) (Table 3B). The two
multivariate models demonstrate the relationship between year of
diagnosis and effect of surgical staging with lymphadenectomy.
DISCUSSION
Prior studies on early-stage ovarian cancer patients have consisted
of a heterogeneous group with respect to risk of recurrence and
survival. These studies have shown that patients with early-stage
disease have overall survival ranging from 60 to 100% (Nguyen
et al, 1993; Kosary, 1994; Averette et al, 1995; Partridge et al, 1996;
Creasman et al, 2003; Jemal et al, 2006). Previous reports on
ovarian cancer survival estimates were based on patients
diagnosed many years ago with outdated estimates (Young et al,
1990; Yancik, 1993). In addition, many of these reports were
limited by the lack of International Federation of Gynecology and
Obstetrics (FIGO) staging and histologic information (Brenner,
2002; Engel et al, 2002; Barnholtz-Sloan et al, 2003). This current
report is one of the largest population-based studies that consist
exclusively of early-stage epithelial ovarian cancer patients with
histologic and surgical information. In over 8000 women
diagnosed with early ovarian cancer, we only showed a marginal
improvement in survival over the last 14 years. Thus, we
determined the factors that are responsible for these findings
based on demographic and clinicopathologic predictors.
Despite the significant progress in treatment of advanced
ovarian cancers over the last 10 years, we have not improved the
survival of young patients. The authors recognise that approxi-
mately 10% of young women with ovarian cancer had germ cell
tumours with survival rates that have reached over 90%. As such, it
may be difficult to detect a survival benefit in these young patients
given that these patients have excellent survivals from their germ
cell cancers. However, the lack of survival improvement in young
women may only be partially explained by the higher proportion
of germ cell tumours compared with the older cohorts. In this
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sstudy, we showed that women o50-years old with early-stage
epithelial ovarian cancer did not have an improvement in survival
over time (Table 2). Some studies have found that a significant
number of these young patients with poor prognostic ovarian
cancers do not undergo adjuvant chemotherapy. Cress et al (2003)
studied 2150 women with ovarian cancer and found that
approximately 20% of patients younger than 55 years with stage
IC and II ovarian cancer did not receive chemotherapy. However,
the likelihood of receiving chemotherapy was significantly
increased if a gynaecologic oncologist was involved in the patient’s
care (Chan et al, 2007a). Furthermore, Asians had a superior
5-year survival at 57.2% compared with African Americans (45.5%)
and Caucasians (46.6%) (Po0.001). A subanalysis revealed that
the Asian patients in our study presented at a younger age, earlier
stage, and lower grade of disease than their counterparts – all
factors that contribute to the better survival in this racial group.
Despite the better survival in early-stage ovarian cancer
compared with advanced stage cancer, there has been no
significant improvement in survival over the years for early
ovarian cancer. In fact, stage II ovarian cancer continues to carry a
3-year survival of 70–77% with no improvement in survival over
the years. Several studies have shown that stage of disease within
those with early-stage cancers is an important prognostic factor
Table 1 Demographic and clinicopathologic characteristics
Total 1988–1992 1993–1997 1998–2001 P-value
Overall 8372 2511 3294 2567
Age at diagnosis (years)
Median (range) 57 (12–99) 58 (12–99) 57 (15–99) 55 (14–97)
Age o50 2799 (33.4%) 836 (33.2%) 1110 (33.7%) 853 (33.2%) 0.917
Age X50 5573 (66.6%) 1675 (66.8%) 2184 (66.3%) 1714 (66.8%)
Race
Caucasian 6564 (78.4%) 2125 (84.6%) 2530 (76.8%) 1909 (74.4%) o0.001
Hispanic 587 (7.0%) 120 (4.8%) 250 (7.6%) 217 (8.5%)
African American 401 (4.8%) 105 (4.2%) 174 (5.3%) 122 (4.7%)
Asian 605 (7.2%) 118 (4.7%) 257 (7.8%) 230 (8.9%)
Other 215 (2.6%) 43 (1.7%) 83 (2.5%) 89 (3.5%)
Surgery
Yes 7945 (94.9%) 2406 (95.8%) 3102 (94.2%) 2437 (94.9%) 0.018
No 427 (5.1%) 105 (4.2%) 192 (5.8%) 130 (5.1%)
Lymphadenectomy
Yes 3327 (39.7%) 659 (26.2%) 1276 (38.7%) 1392 (54.2%) o0.001
No 4360 (52.1%) 1648 (65.6%) 1713 (52.0%) 999 (38.9%)
Unknown 685 (8.2%) 204 (8.1%) 305 (9.3%) 176 (6.9%)
Stage
Stage I 6152 (73.4%) 1853 (73.8%) 2443 (74.2%) 1856 (72.3%) 0.253
Lymphadenectomy 2506 (29.9%) 510 (20.3%) 964 (29.3%) 1032 (40.2%) o0.001
No lymphadenectomy 3120 (37.3%) 1188 (47.3%) 1237 (37.6%) 695 (27.1%)
Stage II 2220 (26.5%) 658 (26.2%) 851 (25.8%) 711 (27.7%)
Lymphadenectomy 821 (9.8%) 149 (5.9%) 312 (9.5%) 360 (14.0%) o0.001
No lymphadenectomy 1240 (14.8%) 460 (18.3%) 476 (14.4%) 304 (11.8%)
Histology
Serous 2214 (26.4%) 671 (26.7%) 847 (25.7%) 696 (27.1%) o0.001
Endometrioid 2230 (26.6%) 574 (22.9%) 875 (26.6%) 781 (30.4%)
Mucinous 1601 (19.1%) 552 (22.0%) 641 (19.5%) 408 (15.9%)
Clear cell 940 (11.2%) 256 (10.2%) 380 (11.5%) 304 (11.8%)
Other 1387 (16.6%) 458 (18.2%) 551 (16.7%) 378 (14.7%)
Grade
Grade 1 1703 (20.3%) 474 (18.9%) 717 (21.8%) 512 (19.9%) 0.010
Grade 2 2163 (25.8%) 635 (25.3%) 834 (25.3%) 694 (27.0%)
Grade 3 2219 (26.5%) 566 (22.5%) 902 (27.4%) 751 (29.3%)
Unknown 2287 (27.3%) 836 (33.3%) 841 (25.5%) 610 (23.8%)
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Figure 1 Kaplan–Meier disease-specific survival by stage (Po0.001).
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s(Schildkraut et al, 2000; Pectasides et al, 2007). Given the poor
prognosis of stage II patients compared with stage I patients, many
investigators have advocated for the inclusions of stage II patients
into clinical trials for advanced (stages III–IV) cancers.
In this study, clear cell tumours have a worse survival compared
with the other histological subtypes. Previous analyses have shown
that clear cell tumours carry a worse prognosis compared with
other epithelial malignancies adjusted for stage of disease (Vergote
et al, 1993). However, other studies have found no significant
difference between clear cell and other epithelial subtypes
(Pettersson, 1988). In our multivariate analyses, clear cell
histology, stage II disease, and poorly differentiated tumours all
were independent factors for poor prognosis. Although it is
reassuring that survival has improved with poorly differentiated
tumours over the years, these findings are not evident in stage II
disease and clear cell histology.
Since 1988, the International Federation of Gynecology and
Obstetrics published guidelines for surgical staging for ovarian
cancer that included pelvic and para-aortic lymph node dissection
or lymphadenectomy. Over time, the use of lymphadenectomy
Table 2 Three-year disease-specific survival
Total (%) 1988–1992 (%) 1993–1997 (%) 1998–2001 (%) Log-rank
Overall 87.2 (±0.4) 86.1 (±0.7) 87.2 (±0.6) 88.8 (±0.8) P¼0.076
Age at diagnosis (years) Po0.001
D
o50 93.1 (±0.5) 93.8 (±0.8) 92.2 (±0.8) 94.0 (±1.1) P¼0.259*
X50 84.2 (±0.5) 82.2 (±1.0) 84.5 (±0.8) 86.3 (±1.1) P¼0.048*
Race P¼0.005
D
Caucasian 87.1 (±0.4) 86.2 (±0.8) 86.7 (±0.7) 88.2 (±1.0) P¼0.374*
Hispanic 88.8 (±1.5) 90.3 (±2.8) 86.7 (±2.2) 91.1 (±2.8) P¼0.395*
African American 84.5 (±2.0) 80.9 (±4.0) 86.3 (±2.7) 85.1 (±4.2) P¼0.213*
Asian 89.4 (±1.4) 84.7 (±3.4) 90.7 (±1.9) 91.0 (±2.6) P¼0.495*
Surgery Po0.001
D
Yes 90.1 (±0.4) 88.4 (±0.7) 90.7 (±0.5) 91.5 (±0.8) P¼0.678*
No 24.8 (±2.6) 22.2 (±4.9) 22.3 (±3.5) 34.1 (±5.2) P¼0.022*
Lymphadenectomy Po0.001
D
Yes 93.3 (±0.5) 93.2 (±1.0) 93.5 (±0.7) 93.1 (±0.9) P¼0.978*
No 82.0 (±0.6) 82.8 (±1.0) 81.2 (±1.0) 82.0 (±1.6) P¼0.211*
Stage Po0.001
D
Stage I 91.8 (±0.4) 91.4 (±0.7) 91.5 (±0.6) 93.4 (±0.8) P¼0.202*
Po0.001
D
Lymphadenectomy 95.2 (±0.5) 95.0 (±1.0) 94.7 (±0.7) 96.3 (±0.8) P¼0.468*
No lymphadenectomy 89.0 (±0.6) 90.0 (±0.9) 88.4 (±0.9) 88.6 (±1.6) P¼0.295*
Stage II 74.2 (±1.0) 70.7 (±1.8) 74.5 (±1.5) 77.3 (±2.1) P¼0.057*
Po0.001
D
Lymphadenectomy 87.4 (±1.3) 87.0 (±2.8) 89.5 (±1.8) 84.3 (±2.7) P¼0.425*
No lymphadenectomy 63.4 (±1.5) 63.2 (±2.4) 62.1 (±2.3) 67.0 (±3.5) P¼0.410*
Histology Po0.001
D
Serous 88.4 (±0.7) 86.6 (±1.3) 89.4 (±1.1) 88.9 (±1.7) P¼0.412*
Endometrioid 93.8 (±0.6) 92.1 (±1.1) 93.5 (±0.8) 96.7 (±0.8) P¼0.015*
Mucinous 92.5 (±0.7) 93.1 (±1.1) 92.9 (±1.0) 90.2 (±1.9) P¼0.460*
Clear cell 85.8 (±1.2) 84.4 (±2.3) 84.9 (±1.9) 87.2 (±3.0) P¼0.863*
Grade Po0.001
D
1 96.4 (±0.5) 96.5 (±0.9) 96.1 (±0.7) 96.6 (±1.1) P¼0.875*
2 92.4 (±0.6) 92.2 (±1.1) 92.1 (±0.9) 93.3 (±1.2) P¼0.676*
3 82.0 (±0.9) 75.9 (±1.9) 83.3 (±1.3) 86.7 (±1.7) Po0.001*
DP-value represents differences in survival of patients o50 vs X50 years, Caucasian vs Hispanics vs African American vs Asian, surgery vs no surgery, lymphadenectomy vs no
lymphadenectomy, Stage I vs Stage II, serous vs endometrioid vs mucinous vs clear cell histologies, and grades 1 vs 2 vs 3. *P-value represents differences in survival over time
based on demographic and clinicopathologic prognostic factors.
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Figure 2 Kaplan–Meier disease-specific survival by histology (Po0.001).
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sduring ovarian cancer surgery has increased. Up to 30% of patients
were found, on prior studies, to be upstaged from early-stage
ovarian cancer during the restaging procedure (Young et al, 1983;
Helewa et al, 1986; Soper et al, 1992). It is also possible that this
association of lymphadenectomy and better survival is attributed
to more appropriate treatment due to more accurate staging. In
our first multivariate model, we found that year of diagnosis was
an independent prognostic factor for improved survival over time
(Table 3A). However, after adjusting for the increased use of
lymphadenectomy over time, the improvement in outcome was no
longer evident (Table 3B). Thus, it is likely that the survival
improvement associated with lymphadenectomy over time is due
to an increase in proportion of true early-stage patients after a
thorough staging procedure, and subsequent removal of inaccu-
rately staged patients with true stage IIIC disease. Similarly, other
reports have described a possible association between lymphade-
nectomy and better survival in early nonclear cell epithelial
ovarian cancer (Chan et al, 2007b). In addition, this association
was attributed to accurate staging leading to appropriate treatment
and, possibly, the removal of micrometastatic disease within the
node, which would have been considered negative on pathological
analyses.
This study is limited by its retrospective design. Even though the
SEER database has value in determining treatment and survival
trends, treatment claims must be used with caution. For example,
there is a lack of information on the specialty of surgeon and
detailed information on the types and cycles of chemotherapy. One
inherent advantage of the SEER database is the ability to generalise
these results in a population comparable to that of the United
States. This is also the largest study, to date, investigating the
survival trends and prognostic factors in early-stage epithelial
ovarian cancer.
The use of lymphadenectomy during surgery for early-stage
ovarian cancer has doubled over the last 14 years. The marginal
improvement in survival demonstrated over time is potentially
attributed to the increased use of staging procedures with
lymphadenectomy.
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Figure 3 Kaplan–Meier disease-specific survival by year (P¼0.076).
Table 3 Multivariate analysis
Prognostic factor Hazard ratio 95% confidence interval P-value
(A) Including lymphadenectomy
Year of diagnosis
a 0.98 0.96–0.99 0.004
Age at diagnosis
a 1.03 1.02–1.03 o0.001
Surgery
b 0.17 0.15–0.20 o0.001
Stage
c 2.45 2.19–2.75 o0.001
Histology
d 1.30 1.20–1.42 o0.001
Grade
e 1.57 1.42–1.73 o0.001
(B) Excluding lymphadenectomy
Year of diagnosis
a 0.99 0.97–1.00 0.098
Age at diagnosis
a 1.03 1.02–1.03 o0.001
Surgery
b 0.19 0.16–0.23 o0.001
Lymphadenectomy
b 0.68 0.59–0.78 o0.001
Stage
c 2.48 2.22–2.78 o0.001
Histology
d 1.28 1.17–1.39 o0.001
Grade
e 1.56 1.43–1.73 o0.001
aContinuous (1988–2001).
bNo vs yes.
cI vs II.
dEndometrioid or mucinous vs serous
or clear cell vs other.
e1 vs 2 vs 3+unknown.
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